Masahiro Takeuchi

Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.

Tanioka H, Shimada K, Tsuji A, Kochi M, Kim HM, Takahashi T, Denda T, Takagane A, Watanabe T, Kotaka M, Nakamura M, Sunakawa YU, Takeuchi M, Ichikawa W, Fujii M.

Anticancer Res. 2022 May. 42(5):2675-2681. PMID: 35489740

A high prevalence of myeloid malignancies in progeria with Werner syndrome is associated with p53 insufficiency.

Kato H, Maezawa Y, Nishijima D, Iwamoto E, Takeda J, Kanamori T, Yamaga M, Mishina T, Takeda Y, Izumi S, Hino Y, Nishi H, Ishiko J, Takeuchi M, Kaneko H, Koshizaka M, Mimura N, Kuzuya M, Sakaida E, Takemoto M, Shiraishi Y, Miyano S, Ogawa S, Iwama A, Sanada M, Yokote K.

Exp Hematol. 2022 May. 109:11-17. PMID: 35240258

Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09.

Tsuji A, Nakamura M, Watanabe T, Manaka D, Matsuoka H, Kataoka M, Takeuchi M, Ichikawa W, Fujii M.

Target Oncol. 2021 11. 16(6):753-760. PMID: 34718946

18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12).

Nakamura M, Satake H, Sagawa T, Takagane A, Sekikawa T, Oguchi K, Kaji T, Takeuchi M, Ichikawa W, Fujii M.

Oncol Ther. 2021 Dec. 9(2):635-645. PMID: 34626349

Successful Pre-Operative Local Control of Skin Invasion of Breast Cancer Using a Combination of Systemic Chemotherapy and Mohs Paste.

Takeuchi M, Katsuki T, Yoshida K, Onoda M, Iwamura M, Inokuchi T, Furutani A, Katoh T, Kawano K, Hirata K.

J Breast Cancer. 2021 Oct. 24(5):481-490. PMID: 34725974

Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation.

Ohwada C, Yamazaki S, Shono K, Kayamori K, Hino Y, Oshima-Hasegawa N, Muto T, Tsukamoto S, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Iseki T, Onoda M, Yokota A, Suzuki T, Ishii I, Nakaseko C, Sakaida E.

Int J Hematol. 2021 Dec. 114(6):664-673. PMID: 34523110

Identification of clonal immunoglobulin ? light-chain gene rearrangements in AL amyloidosis using next-generation sequencing.

Kimura K, Tsukamoto S, Miyazaki K, Kawajiri-Manako C, Ishii A, Rahmutulla B, Fukuyo M, Oshima-Hasegawa N, Mitsukawa S, Takeda Y, Mimura N, Takeuchi M, Ohwada C, Iseki T, Matsusaka K, Sanada M, Yokote K, Kaneda A, Ishida T, Suzuki K, Nakaseko C, Sakaida E.

Exp Hematol. 2021 09. 101-102:34-41.e4. PMID: 34411686

Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.

Mishina T, Oshima-Hasegawa N, Tsukamoto S, Fukuyo M, Kageyama H, Muto T, Mimura N, Rahmutulla B, Nagai Y, Kayamori K, Hino Y, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Tsujimura H, Iseki T, Nakaseko C, Ikeda JI, Itami M, Yokote K, Ohara O, Kaneda A, Sakaida E.

Br J Haematol. 2021 12. 195(5):731-742. PMID: 34378195

Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07.

Kakeji Y, Yoshida K, Kodera Y, Kochi M, Sano T, Ichikawa W, Lee SW, Shibahara K, Shikano T, Kataoka M, Ishiguro A, Ojima H, Sakai Y, Musha N, Takase T, Kimura T, Takeuchi M, Fujii M.

Gastric Cancer. 2022 01. 25(1):188-196. PMID: 34351555

Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.

Shirasuna K, Koelsch G, Seidel-Dugan C, Salmeron A, Steiner P, Winston WM, Brodkin HR, Nirschl CJ, Abbott S, Kinugasa F, Sugahara S, Ohori M, Takeuchi M, Hicklin DJ, Yoshida T.

Cancer Treat Res Commun. 2021. 28:100433. PMID: 34273876